Trastuzumab-pkrb - Biologic Drug Details

Summary for trastuzumab-pkrb

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for trastuzumab-pkrb

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for trastuzumab-pkrb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for trastuzumab-pkrb Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for trastuzumab-pkrb Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Trastuzumab-pkrb

Last updated: February 17, 2026

Trastuzumab-pkrb, marketed as Ogivri, is a biosimilar to Herceptin (trastuzumab). Approved by the FDA in December 2019, it targets HER2-positive breast and gastric cancers. The drug influences the biologics market, particularly within oncology therapeutics.

Market Entry and Regulatory Status

• Approval Date: December 2019 (FDA)
• FDA Designation: Biosimilar, indicating similarity to the reference biologic without clinically meaningful differences
• Patent Landscape: Herceptin's patents expired in 2019, opening market space for biosimilars like trastuzumab-pkrb

Market Penetration and Competitive Position

• Initial Launch: Entered a market with limited biosimilar options and high brand loyalty for Herceptin
• Market Share (2023): Estimated between 10-15% in US oncology biologics segment, with increasing trajectory

Year	Estimated Market Share	Notes
2020	2-3%	Launch year, early adoption by specialty clinics
2021	5-7%	Growing acceptance, inclusion in formularies
2022	8-12%	Expanded payer coverage, increased physician familiarity
2023	10-15%	Steady growth, competitive pressure on reference biologic

• Pricing Strategy: Biosimilar launch prices are approximately 15-30% lower than Herceptin. This pricing creates a significant cost advantage for healthcare providers and payers.

Sales and Revenue Projections

Estimates suggest biosimilar sales will increase as market acceptance grows. For a typical HER2-positive breast cancer indication, global trastuzumab sales exceed $7 billion annually (2022). Biosimilars like trastuzumab-pkrb are projected to account for 30-50% of total trastuzumab consumption within 5 years of market entry.

Year	Estimated Global Sales (USD billion)	Biosimilar Market Share	Key Drivers
2023	1.0 - 1.2	10-15%	Physician familiarity, payer coverage
2024	1.5 - 1.8	20-25%	Expanded geographic markets, increased biosimilar uptake
2025	2.0 - 2.5	30-50%	Patent exclusivities fall further, more biosimilar entries

Market Challenges and Opportunities

• Challenges

  • Limited physician experience with biosimilars affecting prescribing patterns
  • Payer negotiations influencing pricing and formulary placement
  • Competition among multiple biosimilars, including newer entrants

• Opportunities

  • Cost savings driving uptake in institutional settings
  • Expansion into emerging markets with growing cancer treatment needs
  • Off-label uses and combination therapies presenting additional revenue streams

Competitive Landscape

• Existing Biosimilars
  • Trastuzumab-dttb (Trazimra) and others entering markets, creating competition
• Reference Biologic: branded Herceptin remains dominant in many regions, though its share decreases

Financial Implications

• Revenue Potential: Biosimilar revenues could reach USD 500 million globally within five years of entry
• Cost Savings: Estimated annual healthcare savings of USD 3-5 billion across US and European markets due to biosimilar adoption
• Market Growth Rate: Compound annual growth rate (CAGR) for biosimilar trastuzumab approximates 20-25% over the next five years, driven by healthcare policy shifts and cost-pressure environments

---

Key Takeaways

• Trastuzumab-pkrb’s market share increases steadily, driven by pricing advantages and expanded payer coverage.
• Revenue growth depends heavily on geographic expansion, physician acceptance, and competitive biosimilar entries.
• The drug faces a bullish trajectory in emerging markets, where cost constraints accelerate biosimilar adoption.
• Competition among biosimilars and from the reference product will influence long-term pricing and market share.
• Cost savings and increased access position trastuzumab biosimilars as a critical component of oncology care strategies.

---

FAQs

1. What factors influence the market penetration of trastuzumab-pkrb?
Physician familiarity, payer inclusion, pricing strategies, and competitive biosimilars impact market share.

2. How do biosimilar prices compare to Herceptin?
Biosimilars generally are priced 15-30% lower, reducing treatment costs and accelerating adoption.

3. What are the growth prospects for trastuzumab biosimilars?
Global sales could reach USD 2 billion within five years, with a CAGR of 20-25%.

4. What are the primary challenges for trastuzumab-pkrb?
Limited physician experience, payer negotiations, and rising biosimilar competition.

5. How does market expansion vary geographically?
US and Europe show slow, steady growth; emerging markets offer faster expansion due to cost sensitivity.

---

Sources

[1] IQVIA. "Global Oncology Market Data," 2022.
[2] FDA. "Biologics Price Competition and Innovation Act," 2010.
[3] EvaluatePharma. "World Preview 2023," 2023.
[4] IMS Health. "Biosimilar Forecast," 2022.